Physician profile
Peter G Dormas
NPI 1598965709
$4,046.95
in general payments reported to CMS, 2019-2025
25 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $189 · 2021: $190 · 2022: $763 · 2023: $611 · 2024: $710 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367 · Gift: $1.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.37 |
| Gift | $1.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $569.65 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens |
| Bausch & Lomb Americas INC. | $470.30 | 2023-2025 | Miebo, Infuse, Xiidra |
| Sun Pharmaceutical Industries INC. | $452.70 | 2021-2025 | Cequa |
| Alcon Vision LLC | $409.31 | 2019-2025 | Precision7, Tryptyr, Rocklatan |
| Novartis Pharmaceuticals Corporation | $403.12 | 2019-2023 | |
| Oyster Point Pharma, INC. | $341.63 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $222.63 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $221.48 | 2019-2024 | |
| Abbvie INC. | $178.75 | 2022-2023 | Alphagan P, Lumigan, Vuity |
| Abb Con-Cise Optical Group LLC | $144.29 | 2019-2020 | |
| Biotissue Holdings INC. | $100.00 | 2022-2025 | |
| Dompe US, INC. | $89.45 | 2024-2025 | Oxervate |
| Shire North American Group INC | $77.06 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $63.30 | 2025 | Clarus |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.31 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $52.52 | 2024-2025 | Izervay |
| Vantage Technology LLC | $50.51 | 2023 | |
| Allergan, INC. | $22.89 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $19.26 | 2025 | Iyuzeh |
| Optos, INC. | $18.27 | 2019 | |
| Alcon Research LLC | $18.23 | 2019 | |
| Kala Pharmaceuticals, INC. | $16.15 | 2021 | |
| Harrow Eye, LLC | $15.92 | 2024 | Vevye |
| Mallinckrodt Enterprises LLC | $14.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dormas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.